English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/163400
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders

AutorBenek, O.; Pérez Fernández, Daniel Ignacio ; Pérez, Concepción; Martínez, Ana ; Musilek, Kamil
Palabras claveAlzheimer’s disease
Amyloid-beta binding alcohol dehydrogenase (ABAD)
Benzothiazole
Casein kinase 1 (CK1)
Neurodegeneration
Fecha de publicación14-mar-2018
EditorInforma Healthcare
CitaciónJ Enzyme Inhib Med Chem 33(1):665-670 (2018)
ResumenSeveral neurodegenerative disorders including Alzheimer's disease (AD) have been connected with deregulation of casein kinase 1 (CK1) activity. Inhibition of CK1 therefore presents a potential therapeutic strategy against such pathologies. Recently, novel class of CK1-specific inhibitors with N-(benzo[d]thiazol-2-yl)-2-phenylacetamide structural scaffold has been discovered. 1-(benzo[d]thiazol-2-yl)-3-phenylureas, on the other hand, are known inhibitors amyloid-beta binding alcohol dehydrogenase (ABAD), an enzyme also involved in pathophysiology of AD. Based on their tight structural similarity, we decided to evaluate series of previously published benzothiazolylphenylureas, originally designed as ABAD inhibitors, for their inhibitory activity towards CK1. Several compounds were found to be submicromolar CK1 inhibitors. Moreover, two compounds were found to inhibit both, ABAD and CK1. Such dual-activity could be of advantage for AD treatment, as it would simultaneously target two distinct pathological processes involved in disease's progression. Based on PAMPA testing both compounds were suggested to permeate the blood-brain barrier, which makes them, together with their unique dual activity, interesting lead compounds for further development.
Descripción6 p.-2 fig.-2 tab. Benek, O. et al.
Versión del editorhttp://dx.doi.org/10.1080/14756366.2018.1445736
URIhttp://hdl.handle.net/10261/163400
DOI10.1080/14756366.2018.1445736
ISSN1475-6366
E-ISSN1475-6374
Aparece en las colecciones: (CIB) Artículos
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.